• KOL
    • Type 1 Diabetes
    • William V Tamborlane
    • William V Tamborlane: Influence Statistics

      William V Tamborlane

      William V Tamborlane

      Show email address

      University of Michigan, Ann Arbor, MI. | Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA. Electronic address: william.tamborlane@yale.edu. | ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      William V Tamborlane:Expert Impact

      Concepts for whichWilliam V Tamborlanehas direct influence:Type 1 diabetes,Type 1,1 diabetes,Type 2 diabetes,Young children,Diabetes mellitus,Growth hormone,Continuous glucose monitoring.

      William V Tamborlane:KOL impact

      Concepts related to the work of other authors for whichfor which William V Tamborlane has influence:Type 1 diabetes,Metabolic syndrome,Insulin resistance,Blood glucose,Glycemic control,Obese children,Growth hormone.

      KOL Resume for William V Tamborlane

      Year
      2022

      University of Michigan, Ann Arbor, MI.

      Yale School of Medicine, New Haven, CT, USA.

      2021

      Yale University School of Medicine, New Haven, Connecticut, USA.

      New Haven, CT, Gaithersburg, MD, Los Angeles, CA, Haifa, Israel, Kuwait City, Kuwait, Baja, Hungary, Cambridge, United Kingdom, Mölndal, Sweden

      2020

      Yale School of Medicine, Department of Pediatric Endocrinology and Diabetes, New Haven, Connecticut.

      2019

      Yale School of Medicine, New Haven, Connecticut

      Stanford, CA, Palo Alto, CA, Jacksonville, FL, St. Louis, MO, New Haven, CT, Iowa City, IA

      2018

      Pediatric Endocrinology, Yale University, New Haven, CT, USA

      Yale University School of Medicine, New Haven, CT

      2017

      Department of Pediatric Endocrinology, Yale University, New Haven, Connecticut, USA

      Yale School of Medicine, New Haven, Connecticut.

      Washington University in St. Louis, St. Louis, MO

      2016

      Department of Pediatric Endocrinology and Yale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT

      Yale University School of Medicine, New Haven, Connecticut

      2015

      a 1 Yale University, Department of Pediatrics , PO Box 208064, New Haven, CT 06520-8064, USA +1 203 785 7924 ; +1 203 737 2829 ;

      2014

      1, Section of Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT

      Department of Pediatrics Yale School of Medicine New Haven Connecticut

      2013

      Department of Pediatrics, Yale University School of Medicine New Haven CT USA

      Pediatric Endocrinology, Yale University, New Haven, Connecticut.

      7, Yale University, New Haven, Connecticut

      2012

      Yale University School of Medicine, 333 Cedar Street, PO Box 208064, 06520, New Haven, CT, USA

      Editor-in-Chief

      Diabetes Technology Therapeutics Professor of Medicine and Pediatrics Endowed Chairs Director Adult Program Barbara Davis Center for Childhood Diabetes University of Colorado Denver, CO

      Sign-in to see all concepts, it's free!
      Sample of concepts for which William V Tamborlane is among the top experts in the world.
      Concept World rank
      young adult smbg #1
      obese youth langerhans #1
      challenges potential benefits #1
      a1c secondary study #1
      dka knowledge #1
      workup hypoglycemia #1
      cst idm #1
      alcohol illicit suds #1
      limitations sensors #1
      robustness envelope controller #1
      cgm african americans #1
      mdi subjects #1
      glycemia young children #1
      nhw comorbidities #1
      treatment option attainment #1
      objective csii #1
      cgmfbi #1
      symptoms dka #1
      insulin sensitivity degree #1
      cgms calibration #1
      hba1c 82 #1
      t1dm clinicians #1
      severe hypoglycemia age #1
      iddm effects #1
      persistence benefits #1
      t1dm 3 groups #1
      adequate control metformin #1
      challenges young adult #1
      antecedent exercise control #1
      health qualitative cgm #1
      children diabetes technology #1
      exercise overnight hypoglycemia #1
      prepump #1
      δgon #1
      cgm parental fear #1
      total 70 #1
      consortium t1d #1
      neuropathy diagnoses #1
      baseline hba1c 88 #1
      11 22 hypoglycemia #1
      optimized mdi #1
      afinion hemoglobin #1
      hba1c 818 cohort #1
      70 39 mmol #1
      dcct recommendations #1
      insulinsparing manner #1
      t2d 92 #1
      negligible hypoglycemia #1
      hypoglycemia exercise nights #1
      insulin infusion postp #1
      Sign-in to see all concepts, it's free!

      Prominent publications by William V Tamborlane

      KOL-Index: 16753

      IMPORTANCE: Previous studies assessing the effect of metformin on glycemic control in adolescents with type 1 diabetes have produced inconclusive results.

      OBJECTIVE: To assess the efficacy and safety of metformin as an adjunct to insulin in treating overweight adolescents with type 1 diabetes.

      DESIGN, SETTING, AND PARTICIPANTS: Multicenter (26 pediatric endocrinology clinics), double-blind, placebo-controlled randomized clinical trial involving 140 adolescents aged 12.1 to 19.6 years ...

      Known for Glycemic Control | Type 1 Diabetes | Participants Metformin | Placebo Difference | Baseline Hba1c
      KOL-Index: 15559

      CONTEXT: Pediatric obesity has escalated to epidemic proportions, leading to an array of comorbidities, including type 2 diabetes in youth. Since most overweight children become overweight adults, this chronic condition results in serious metabolic complications by early adulthood. To curtail this major health issue, effective pediatric interventions are essential.

      OBJECTIVE: To compare effects of a weight management program, Bright Bodies, on adiposity and metabolic complications of ...

      Known for Overweight Children | Weight Management | Body Composition | Randomized Controlled Trial | 12 Months
      KOL-Index: 14591

      BACKGROUND: Childhood obesity, epidemic in the United States, has been accompanied by an increase in the prevalence of type 2 diabetes among children and adolescents. We determined the prevalence of impaired glucose tolerance in a multiethnic cohort of 167 obese children and adolescents.

      METHODS: All subjects underwent a two-hour oral glucose-tolerance test (1.75 g [DOSAGE ERROR CORRECTED] of glucose per kilogram of body weight), and glucose, insulin, and C-peptide levels were measured. ...

      Known for Impaired Glucose Tolerance | Glucose Insulin | Adolescents Prevalence | 2 Diabetes Children | Marked Obesity
      KOL-Index: 14481

      BACKGROUND: Sensor-augmented pump therapy (SAPT) integrates real-time continuous glucose monitoring (RT-CGM) with continuous subcutaneous insulin infusion (CSII) and offers an alternative to multiple daily injections (MDI). Previous studies provide evidence that SAPT may improve clinical outcomes among people with type 1 diabetes. Sensor-Augmented Pump Therapy for A1c Reduction (STAR) 3 is a multicenter randomized controlled trial comparing the efficacy of SAPT to that of MDI in subjects ...

      Known for Type 1 Diabetes | Multiple Daily Injections | Baseline Characteristics | Sapt Mdi | Insulin Pump
      KOL-Index: 13910

      OBJECTIVE: The efficacy of the insulin analogs now available for multiple daily injection (MDI) and continuous subcutaneous insulin infusion (CSII) therapy in type 1 diabetes has not yet been established in pediatric patients. Our principal aim in this short-term study was to compare the efficacy of CSII to MDI with glargine in lowering HbA(1c) levels in children and adolescents with type 1 diabetes.

      RESEARCH DESIGN AND METHODS: Thirty-two youth with type 1 diabetes (age 8-21 years) were ...

      Known for Csii Glargine | Subcutaneous Insulin | Multiple Daily Injections | 16 Weeks | Type 1 Diabetes
      KOL-Index: 13617

      BACKGROUND: The prevalence and magnitude of childhood obesity are increasing dramatically. We examined the effect of varying degrees of obesity on the prevalence of the metabolic syndrome and its relation to insulin resistance and to C-reactive protein and adiponectin levels in a large, multiethnic, multiracial cohort of children and adolescents.

      METHODS: We administered a standard glucose-tolerance test to 439 obese, 31 overweight, and 20 nonobese children and adolescents. Baseline ...

      Known for Metabolic Syndrome | Obesity Prevalence | Adiponectin Levels | Insulin Resistance | Obese Children Adolescents
      KOL-Index: 13234

      Aims/hypothesisThe study aimed to compare participant characteristics, treatment modalities and clinical outcomes in registry participants less than 6 years old.MethodsParticipant characteristics, treatment modalities and clinical outcomes (HbA1c, severe hypoglycaemia [SH] and diabetic ketoacidosis [DKA]) as well as frequencies of attaining HbA1c goals in line with the International Society for Pediatric and Adolescent Diabetes (<7.5% [<58 mmol/mol]) and ADA (<8.5% [<69 mmol/mol]) were ...

      Known for United States | Type 1 | 6 Years | Dpv Registries | Preschool Diabetes Mellitus
      KOL-Index: 13128

      BACKGROUND: The safety and effectiveness of the in-home use of a hybrid closed-loop (HCL) system that automatically increases, decreases, and suspends insulin delivery in response to continuous glucose monitoring were investigated.

      METHODS: Adolescents (n = 30, ages 14-21 years) and adults (n = 94, ages 22-75 years) with type 1 diabetes participated in a multicenter (nine sites in the United States, one site in Israel) pivotal trial. The Medtronic MiniMed® 670G system was used during a ...

      Known for Insulin Delivery | Adolescents Adults | Type 1 Diabetes | Glucose Outcomes | Study Phase
      KOL-Index: 13074

      To determine the relationship between circulating metabolic fuels and their local concentrations in peripheral tissues we measured glycerol, glucose, and amino acids by microdialysis in muscle and adipose interstitium of 10 fasted, nonobese human subjects during (a) baseline, (b) euglycemic hyperinsulinemia (3 mU/kg per min for 3 h) and, (c) local norepinephrine reuptake blockade (NOR). At baseline, interstitial glycerol was strikingly higher (P < 0.0001) in muscle (3710 microM) and ...

      Known for Amino Acids | Adipose Tissue | Skeletal Muscle | Interstitial Glucose | Plasma Glycerol
      KOL-Index: 12396

      BACKGROUND: Increasing numbers of children and adolescents with type 1 diabetes (T1D) have been placed on insulin pump therapy. Nevertheless, data are limited regarding patterns of pump use during the first year of treatment and the clinical and socioeconomic factors associated with early use of pump therapy. Therefore, we sought to determine factors associated with pump therapy within the first year of diagnosis in youth enrolled in the Pediatric Diabetes Consortium (PDC) T1D New-Onset ...

      Known for Pump Therapy | Socioeconomic Status | 1 Diabetes | Year Diagnosis | Insulin Infusion
      KOL-Index: 12350

      OBJECTIVE: Hypoglycemia in young children with type 1 diabetes is an acute complication of intensive insulin therapy and is commonly observed in the absence of signs or symptoms. The effect of intensive treatment and patient age on sympathoadrenal responses has not been established in youth with type 1 diabetes because of difficulties in testing procedures.

      RESEARCH DESIGN AND METHODS: We developed a standardized inpatient continuous subcutaneous insulin infusion protocol to produce a ...

      Known for Young Children | Type 1 Diabetes | Plasma Glucose | Hormone Responses | Symptoms Hypoglycemia
      KOL-Index: 12187

      OBJECTIVE: To determine whether initial effects on metabolic control and quality of life associated with a behavioral intervention combined with intensive diabetes management (IDM) can be sustained over 1 year in youth implementing intensive therapy regimens.

      STUDY DESIGN: Seventy-seven patients (43 females, 95% white) 12 to 20 years (mean = 14.2 +/- 1.9; duration, 8.7 +/- 3.9) electing to initiate IDM were randomly assigned to one of two groups: with or without coping skills training ...

      Known for Metabolic Control | Skills Training | Quality Life | Diabetes Mellitus | Behavioral Intervention

      Key People For Type 1 Diabetes

      Top KOLs in the world
      #1
      John M Lachin
      type 1 diabetes cardiovascular disease complications trial
      #2
      David Matthew Nathan
      type 2 diabetes insulin resistance cardiovascular disease
      #3
      William V Tamborlane
      type 1 diabetes young children growth hormone
      #4
      Patricia A Cleary
      type 1 diabetes optic neuritis intensive therapy
      #5
      George S Eisenbarth
      type 1 diabetes nod mice celiac disease
      #6
      Marian J Rewers
      type 1 diabetes islet autoimmunity celiac disease

      University of Michigan, Ann Arbor, MI. | Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA. Electronic address: william.tamborlane@yale.edu. | Department of Pediatrics, Yale University, New Haven, Connecticut. | Yale Sc

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.